A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai's Nuance Pharma in a $225 million deal. The agreement ...

This study is being conducted by Verona's partner in Greater China, Nuance Pharma. Results from the trial are expected in 2025. When we alerted readers to VRNA on May 17, 2024, it was trading at ...